A novel mutation in FBN1 gene in autosomal dominant Marfan syndrome and macular degeneration in a Chinese consanguineous family

Ping-Bo Ouyang¹,², Yuan Zhao³, Ying-Qian Peng¹,², Lu-Si Zhang¹,², Jian Cao¹,², Yun Li¹,²

¹Department of Ophthalmology, the Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China
²Hunan Clinical Research Center of Ophthalmic Disease, Changsha 410011, Hunan Province, China
³Department of Cardiovascular Surgery, the Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China

Correspondence to: Yun Li. Department of Ophthalmology, the Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha 410011, Hunan Province, China. yun.li@csu.edu.cn

Received: 2018-06-10 Accepted: 2018-12-17

Abstract

AIM: To report a novel mutation in FBN1 gene in a Chinese consanguineous family with common Marfan syndrome (MFS) phenotype and an unusual bilateral macular degeneration.

METHODS: Ophthalmic, cardiovascular and systemic examinations were performed, and genomic DNA extracted from all living family members. The 24-32 exon mutations of FBN1 gene were screened by Sanger Sequencing in all family members and 100 unrelated healthy Chinese individuals.

RESULTS: In the four-generation family, classic MFS phenotypes were observed in all 5 patients, 2 of them had peculiar phenotype of bilateral macular degeneration. Mutation screening in FBN1 identified a heterozygous missense mutation (c.3932A>G, p.Y1311C) with co-segregation. This mutation was found with the MFS phenotypes in all 5 patients but not in unaffected members or unrelated controls.

CONCLUSION: A Chinese consanguineous MFS family with uncommon bilateral macular degeneration and an unreported c.3932A>G mutation in FBN1 was identified. Our finding expands the FBN1 mutation spectrum and its possible role in the pathogenesis of Marfan syndrome.

KEYWORDS: Marfan syndrome; fibrillin-1; autosomal dominant; heterozygous mutation

DOI:10.18240/ijo.2019.05.05

INTRODUCTION

Marfan syndrome (MFS; MIM #154700), incidence 1/5000-1/10 000, is an autosomal dominant disorder in which fibrous connective tissue all over the body can be affected¹⁻². Mostly presented manifestations are in cardiovascular, skeletal, ocular, pulmonary and nervous systems. Ocular signs include ectopia lentis, high myopia, peripheral retinal degeneration and rhegmatogenous detachment, etc³⁻⁴. Diagnosis of MFS is based on both clinical criteria and genetic test⁵⁻⁷. For example, a major clinical manifestation plus an FBN1 mutation is enough to confirm the diagnosis⁸. FBN1 (location: 15q-21, 65 exons) is the major causative gene accounting for 90% of MFS cases⁹⁻¹⁰. FBN1 codifies fibrillin-1, a 350-kDa glycoprotein macromolecule that polymerizes to form microfibrils, which serves mechanical support in connective tissue throughout the body¹¹⁻¹². It also regulates microfibril assemble and stability¹². Therefore, FBN1 mutations leads to fibrillin-1 disruption, microfibril malformation, and eventually the attenuation of connective tissues¹³⁻¹⁴.

Most FBN1 mutations are unique for specific MFS families, while 15% of them recur among different pedigrees¹¹. We report a missense mutation in exon 32 of FBN1 (c.3932A>G), resulting in a tyrosine to cysteine change at codon 1443 (p.Y1311C). This mutation was identified in a 4-generation Chinese family with typical MFS signs together with a peculiar macular degeneration. To the best of our knowledge, neither the mutation nor this macular lesion has been reported in MFS before.

SUBJECTS AND METHODS

Ethical Approval  This study was approved by the Ethics Committee on Clinical Investigations of the Second Xiangya Hospital of Central South University, and carried out in accordance with the Declaration of Helsinki for Human Subjects. All participants were given informed consent, and then underwent ophthalmologic, cardiovascular and systemic physical examinations.
Patients and the Clinical Data  Diagnosis of MFS were confirmed according to the revised Ghent criteria.[4] Clinical data were collected from 14 living family members (five patients: II:5, II:7, III:4, III:5, III:9; nine unaffected family members: II:1, II:6, II:8, III:1, III:3, III:10, III:11, IV:1 and IV:2) in the pedigree, all family members received systemic review and ophthalmic examination for MFS-relevant abnormalities, including physical examination, chest X-ray, cardiac ultrasonography, best corrected visual acuity (BCVA), slit lamp examination and indirect ophthalmoscopy. Photography of the anterior segment and funduscopy were recorded if any abnormality presented. Optical coherence tomography (OCT) images (Topcon 3D 2000, Japan) centered on the fovea showed structural changes.

DNA Sample Collection and Sanger Sequencing of FBN1 Gene Genomic DNA extraction were performed using peripheral blood lymphocytes following the standard phenol-chloroform method. DNA samples of patients were used for polymerase chain reaction (PCR) amplification of exon 24, 25, 26, 27, 28, 30, 31, and 32. DNA samples of other family members and 100 normal controls were amplified on exon 32. Primer sequences as follow:

FBN1-24-F: 5'-GGGCTCGTCTGTTGCTA-3', FBN1-24-R: 5'-TCTGTCTATTATTGAAAGACTGT-3', FBN1-25-F: 5'-TTATAGGCAAGGATACTTACC-3', FBN1-25-R: 5'-GGACTTTCTGAGCAACATG-3', FBN1-26-27F: 5'-AAGGCTAGAAATGTTTACAAAGTCA-3', FBN1-26-27R: 5'-TTCCTCATTCTTTTCTACCTCAGT-3', FBN1-28-29-F: 5'-CCATTTTGTGATTAGTCTGAT-3', FBN1-28-29-R: 5'-CGAGGAAAAGAAAGATAAG-3', FBN1-30-F: 5'-ATCCCACCATGAGGGTAGAG-3', FBN1-30-R: 5'-TATGCAGGCAATTTGAACTTC-3', FBN1-31-F: 5'-TTTACCAAGGATAACCCAATG-3', FBN1-31-R: 5'-ATGCTCGTTCTGGTTGCTA-3', FBN1-32-R: 5'-ATGCTACCTGGAATAATG-3', FBN1-32-F: 5- circulation tools Clustal Omega (http://www.ebi.ac.uk/Tools/msa/). Software SIFT (http://sift.jcvi.org/www/SIFT_enst_submit.html) were used to perform functional prediction, PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), and Mutation Taster (http://www.mutationtaster.org/) to score nonsynonymous variant.

RESULTS

Clinical Findings The proband is from a 4-generation consanguineous Chinese family consisting of 13 men and 8 women (pedigree shown in Figure 1A). Of 5 individuals in this pedigree were confirmed with the diagnosis MFS, clinical features were shown in Table 1. The median onset age of the patients was 29y, ranging from 22 to 62y. All 5 patients had typical ocular, skeletal and cardiovascular manifestations. Common MFS skeletal abnormalities like dolichostenomelia, pectus excavatum/carinatum, and scoliosis, joint laxity and arachnodactyly were observed in all affected family members. Cardiovascular findings including aortic aneurysm, tricuspid/mitral valve insufficiency, tricuspid/aortic valve regurgitation, mitral valve prolapse were noted in patient III:5 and III:9, both received Bentall surgery. Shared ophthalmic findings include high myopia, bilateral lens dislocation, and peripheral retinal degeneration. The proband III:4 presents with an acute angle-closure glaucoma secondary to anteriorly dislocated lens after mild trauma in the left eye (Figure 1B-1D). She had lensectomy and scleral fixated intraocular lens (SF-IOL) implantation in both eyes. Her visual acuity is 0.4 for her better eye, and 0.2 for worse eye. Moreover, the proband and her brother (III:5)
present an unusual bilateral macular degeneration appearance in both eyes (Figure 1E-1L). Patient II:3 deceased of dissecting aneurysm at the age of 30, his off-springs III:6, III:7, and III:8 all died in utero or at very early age with “reasons unidentified”.

Genetic Analysis Identified \( \text{FBN1} \) Heterozygous Missense Mutation DNA sample of our proband III:4 were performed PCR and Sanger sequencing to find out mutations in exons 24, 25, 26, 27, 28, 30, 31, and 32, for mutants in these exons are often associated with early onset, prominent MFS phenotypes. Genetic analysis detected a heterozygous missense mutation c.3932A>G (hg37, NM_000138) in our proband, which lead to a mutant protein p.Y1311C. The mutation has not been reported in dbSNP database (https://www.ncbi.nlm.nih.gov/snp) and 1000 Genome (https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/). We performed Sanger sequencing to confirm the co-segregation status in all patients and normal relatives in the family. We found the mutation was consistent with the phenotypes in the family. We assessed this variant in 100 normal controls furtherly and found no mutation at this locus (Figure 2A).
To explore possible impact of the missense mutation on FBN1 protein function, we performed the conservation and function prediction through Clustal Omega, MutatinTaster, Polyphen-2 and SIFT on our mutant. Clustal Omega result predicted asterisks in the amino acid position 1311 (Figure 2B), which indicated highly conserved amino acid on this site. As shown in Table 2, MutationTaster predicted that p.Y1311C was disease causing nucleotide substitution. Both Polyphen-2 and SIFT results demonstrated that the mutation was very likely a damaging nucleotide variation. Conservative functional analysis tools predicted that p.Y1311C mutation probably affected the structure and function of human fibrillin-1 protein.

**Discussion**

Over 3000 FBN1 mutations have been reported in the Universal Marfan Mutation Database (UMD-FBN1; http://www.umd.be/FBN1/), in which 60.3% were missense mutations\(^{[15]}\). In this study we have identified a novel FBN1 heterozygous missense mutation (c.3932A>G, p.Y1311C) in our pedigree. This mutation causes tyrosine to cysteine substitution at the 1311\(^{\text{th}}\) amino acid, which could result in abnormality of fibrillin-1 in the heterozygous affected individuals. Fibrillin-1 molecular structure comprises of 47 epidermal growth factor-like (EGF) domains and seven transforming growth factor-β1 binding protein-like (TB) domains, most mutations of FBN1 appeared
in the EGF domains which could disrupt formation of microfibril, the vital component of extracellular matrix (ECM) and collagen universally expressed in connective tissues in major vessels, cartilages, tendons, corneas, zonules, etc. Fibrillin-1 also functions as an important regulator of TGFβ pathway through forming complex with TGFβ binding protein (LTBPs), and microfibrils. Since our p.Y1311C mutation was predicted to disrupt the biological function or structure of FBN1 protein, it is very likely to disrupt microfibril formation and subsequently cause MFS. Individuals in this pedigree with heterozygous mutation have MFS phenotypes, which is coincident with other study that missense mutation often cause ectopia lentis. Moreover, our pedigree showed a very unusual phenotype of symmetrical bilateral macular degeneration in addition to common phenotype like ectopia lentis, arachnodactyly and scoliosis. Fundus photography showed symmetrical bilateral macular lesions in the proband and her living brother, OCT further revealed an uncommon lesion for MFS in the outer retinal layers: thinning of outer nuclear layer, disruption of external limiting membrane and photoreceptor layers, and accumulation of hyper-reflective material between the neurosensory retina and RPE under the fovea. These changes all imply degenerated photoreceptors in the foveal area, hyperreflective material may correspond to clumping of abnormal photoreceptor outer segments material. As far as we are concerned, this feature has never been reported in Marfan syndrome. Our hypothesis is the microfibrils in photoreceptor-RPE interdigitation and Bruch’s membrane is also affected in this mutation, so the RPE-Bruch’s membrane-choriocapillaris complex is unhealthy and degenerates with time.

In our study, a novel mutation of FBN1 c.3932A>G in exon 32 was identified in a Chinese consanguineous MFS family with an unusual phenotype of macular degeneration. The result not only expands our knowledge of FBN1 mutations, but also is helpful in definite diagnosis of uncertain MFS cases. The genotype-phenotype relationship of the new mutation and its usual sign of bilateral macular degeneration needs to be identified by further study.

**ACKNOWLEDGEMENTS**

We are grateful to all the patients, their unaffected family members, and the healthy volunteers for their participation. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions:** Li Y and Zhao Y analyzed and interpreted the patient data regarding the Marfan syndrome. Ouyang PB, Cao J and Zhao Y performed the patients and the clinical data. Zhang LS performed the genetic analysis. Peng YQ and Cao J was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

**Foundations:** Supported by National Natural Science Foundation of China (No.81300798); Project supported by the National Science Foundation of Hunan Province, China (No.2018JJ3737); Department of Science and Technology, Hunan (No.2015TP2007).

**Conflicts of Interest:** Ouyang PB, None; Zhao Y, None; Peng YQ, None; Zhang LS, None; Cao J, None; Li Y, None.

**REFERENCES**

A novel FBN1 mutation in Marfan syndrome

gene favors locus homogeneity of classical Marfan syndrome. Hum Mutat 2004;24(2):140-146.
13 Zeyer KA, Reinhardt DP. Engineered mutations in fibrillin-1 leading to Marfan syndrome act at the protein, cellular and organismal levels. Mutat Res Rev Mutat Res 2015;765:7-18.